Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

by Collins, Shauna M., Bakan, Courtney E., Swartzel, Gina D., Hofmeister, Craig C., Efebera, Yvonne A., Kwon, Hakju, Starling, Gary C., Ciarlariello, David, Bhaskar, Shakthi, Briercheck, Edward L., Hughes, Tiffany, Yu, Jianhua, Rice, Audie, Benson, Don M.
Published 2013

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

by Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.
Published 2011